Ann: Results from Data Confirmation Study, page-238

As @poorinvestor pointed out earlier, this result confirms that ResApp cough algorithms are capable of distinguishing between upper respiratory tract and lower respiratory tract diseases. This Confirmation study simply was an attempt to use a LRT algorithm to diagnose an URT disease.

Since first appearing the SARS-CoV-2 virus has evolved in a manner similar to those of previous respiratory pandemics. Over a couple of years they have moved from a highly dangerous form to become more contagious but less severe, eventually becoming mild and endemic to continually return as one of the many forms of the ‘common cold’.

In this case earlier viral strains, including the Delta form that was the basis for the COVID Algorithm, infected the whole tract down to the lung aioli, producing effects similar to severe pneumonia. In contrast the Omicron forms have been shown to primarily target sites no lower than the trachea and bronchi, more like a heavy cold, so that with suitable care taken the dangerous pneumonic effects can be avoided.

What the Company now has is over 1300 clinical data that correspond to the new URT COVID forms that can be expected to persist from now on. Feeding that data through the same development procedure would produce a preliminary URT Algorithm suitable for diagnosing the current and future milder form of COVID.

Although more clinical data should be collected, in terms of being able to test for those new URT forms the Company really has only lost a few months by playing around with a clinical data set that is no longer relevant (having wasted 18 months before collecting it). At least the necessary algorithm development process already has been established and Pfizer has supplied funding to take it forward via its licence.

Pfizer no doubt is completely aware of the situation, and as I indicated yesterday this likely was a primary reason for the Confirmation study. It would be encouraging to be able to believe that Management has a similar understanding of the science of the disease that it is targeting, particularly as it doesn’t appear to have a real concept of the true value of the Company it is directing.